進行子宮内膜癌に対する二次治療としてのBKM120

基本情報

NCT ID

NCT01289041

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

70

治験依頼者名

Novartis

概要

This is a prospective multi-center, open-label, single arm, Phase II study to investigate the safety and efficacy of BKM120 in patients with advanced endometrial carcinoma whose disease progressed on or after a first-line antineoplastic treatment. Patients will receive BKM120 orally at a dose of 100 mg/day. Availability of tumor specimen (either archival tissue or a fixed fresh biopsy) is mandatory for assessment of the PI3K (Phosphatidylinositol 3 Kinase (PI3K) pathway activation status.

対象疾患

介入

依頼者（Sponsor）